Publications from HERM

Selected publications from Center for Hematology and Regenerative Medicine (HERM). The publications are listed after each research group responsible for the publication.

Additional publications are also listed on each research group page.

Explanations

*Co-authoring other PIs at HERM
#Shared first or last authorship
 

Evren Alici

  1. Haroun-Izquierdo, A., Vincenti, M., Netskar, H., van Ooijen, H., Zhang, B., Bendzick, L., Kanaya, M., Momayyezi, P., Li, S., Wiiger, M. T., Hoel, H. J., Krokeide, S. Z., Kremer, V., Tjonnfjord, G., Berggren, S., Wikström, K., Blomberg, P., Alici, E., Felices, M., . . . Sohlberg, E. (2022). Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia. J Immunother Cancer, 10(11). https://doi.org/10.1136/jitc-2022-005577  
  2. Nahi, H., Chrobok, M., Meinke, S., Gran, C., Marquardt, N., Afram, G., Sutlu, T., Gilljam, M., Stellan, B., Wagner, A. K., Blomberg, P., Holmqvist, P. H., Walther-Jallow, L., Mellström, K., Liwing, J., Gustafsson, C., Månsson, R., Klimkowska, M., Gahrton, G., Alici, E. (2022). Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. Cell Rep Med, 3(2), 100508. https://doi.org/10.1016/j.xcrm.2022.100508  *
  3. Neo, S. Y., Jing, X., Tong, L., Tong, D., Gao, J., Chen, Z., De Los Santos, M. C., Burduli, N., De Souza Ferreira, S., Wagner, A. K., Alici, E., Rolny, C., Cao, Y., & Lundqvist, A. (2022). Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells. J Immunother Cancer, 10(10). https://doi.org/10.1136/jitc-2022-005308  
  4. Susek, K. H., Schwietzer, Y. A., Karvouni, M., Gilljam, M., Keszei, M., Hussain, A., Lund, J., Kashif, M., Lundqvist, A., Ljunggren, H. G., Nahi, H., Wagner, A. K., & Alici, E. (2022). Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-022-03317-y  *
  5. Karvouni, M., Vidal-Manrique, M., Susek, K. H., Hussain, A., Gilljam, M., Zhang, Y., Gray, J. D., Lund, J., Kaufmann, G., Ljunggren, H. G., Ji, H., Lundqvist, A., Wagner, A. K., Guo, W., & Alici, E. (2023). Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide. Cytotherapy. https://doi.org/10.1016/j.jcyt.2023.03.006  *
     

Yenan Bryceson

  1. Zitti B, Hoffer E, Zheng W, Pandey RV, Schlums H, Perinetti Casoni G, Fusi I, Nguyen L, Kärner J, Kokkinou E, Carrasco A, Gahm J, Ehrström M, Happaniemi S, Keita ÅV, Hedin CRH, Mjösberg J, Eidsmo L#, Bryceson YT#: Human skin-resident CD8+ T cells require RUNX2 and RUNX3 for induction of cytotoxicity and expression of the integrin CD49a. Immunity (2023) 56: 1285-1302.e7. https://doi.org/10.1016/j.immuni.2023.05.003.
  2. Helm EY, Zelenka T, Cismasiu VB, Islam S, Silvane L, Zitti B, Holmes TD, Drashansky TT, Kwiatkowski AJ, Tao C, Dean J, Obermayer AN, Chen X, Keselowsky BG, Zhang W, Huo Z, Zhou L, Sheridan BS, Conejo-Garcia JR, Shaw TI, Bryceson YT, Avram D: Bcl11b sustains multipotency and restricts effector programs of intestinal-resident memory CD8+ T cells. Science Immunol (2023) 8:eabn0484. https://doi.org/10.1126/sciimmunol.abn0484.
  3. Campbell TM, Liu Z, Zhang Q, Moncada-Velez M, Covill LE, Alavi Darazam I, Bastard P, Bizien L, Bucciol G, Enoksson SL, Jouanguy E, Karabela SN, Khan T, Kendir Demirkol Y, Arias AA, Mansouri D, Marits P, Marr N, Migeotte I, Moens L, Ozcelik T, Pellier I, Sendel A, Shahrooei M, Smith CIE, Vandernoot I, Willekens K, COVID Human Genetic Effort, Bergman P, Abel L, Cobat A, Casanova JL#, Meyts I#, Bryceson YT#: Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency. J Exp Med (2022) 219 (8):e20220131. https://doi.org/10.1084/jem.20220202.
  4. Holmes T, Pandey RV, Helm E, Schlums H, Campbell T, Han H, Chiang SC, Shoukier M, Marsh RA, Sun MI, Månsson R, Cichocki F, Avram D, Bryceson YT: The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation. Science Immunol (2021) 6 :eabc9801. https://doi.org/10.1126/sciimmunol.abc9801 .
  5. KalinichenkoA, Perinetti Casoni G, Dupré L, Trotta L, Huemer J, Galgano D, German Y, Haladik B, Chiang SC, Taskinen M, Hekkala A, KauppilaS, Tapiainen T, Kraakman MJ, Vettenranta K, Saarela J#, Seppänen M#, Bryceson YT#, Boztug K*: RhoG controls degranulation in human lymphocytes by cooperating with Munc13-4 to dock lytic granules on the plasma membrane. Blood (2021) 137: 2033-2045. https://doi.org/10.1182/blood.2020008738.   

Mattias Carlsten

  1. Sanz-Ortega L, Andersson A, Carlsten M. Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow. Leukemia. 2023. https://doi.org/10.1038/s41375-023-02126-1. In press
  2. Segerberg F, Lambert M, Sanz-Ortega L, Andersson A, Childs RW, Carlsten M. Improved leukemia clearance after adoptive transfer of NK cells expressing the bone marrow homing receptor CXCR4-R334X. HemaSphere. 2023 Nov 7(11):p e974. | https://doi.org/10.1097/HS9.0000000000000974.
  3. Palau A, Segerberg F, Lidschreiber M, Lidschreiber K, Naughton AJ, Needhamsen M, Jung LA, Jagodic M, Cramer P, Lehmann S#, Carlsten M#, Lennartsson A#. Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells. Leukemia. 2023 Sep;37(9):1830-1841. https://doi.org/10.1038/s41375-023-01972-3. Epub 2023 Jul 26. *
  4. Daly J, Sarkar S, Natoni A, Stark JC, Riley NM, Bertozzi CR, Carlsten M#, O'Dwyer ME#. Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses. Blood Adv. 2022 Jun 14;6(11):3352-3366. https://doi.org/10.1182/bloodadvances.2021006805.
  5. Leijonhufvud C, Reger R, Segerberg F, Theorell J, Schlums H, Bryceson YT, Childs RW, Carlsten M. LIR-1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibody-dependent cellular cytotoxicity. Clin Transl Immunology. 2021 Oct 5;10(10):e1346. https://doi.org/10.1002/cti2.1346. eCollection 2021. *

Roland Fiskesund

  1. Fiskesund, R., J. Steen, K. Amara, F. Murray, A. Szwajda, A. Liu, I. Douagi, V. Malmström and J. Frostegård (2014). Naturally occurring human phosphorylcholine antibodies are predominantly products of affinity-matured B cells in the adult. J Immunol 192(10): 4551-4559. https://doi.org/10.4049/jimmunol.1303035.
  2. Karsten, S., R. Fiskesund, X. M. Zhang, P. Marttila, K. Sanjiv, T. Pham, A. Rasti, L. Bräutigam, I. Almlöf, M. Marcusson-Ståhl, C. Sandman, B. Platzack, R. A. Harris, C. Kalderén, K. Cederbrant, T. Helleday, and U. Warpman Berglund. 2022. MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells. Cell Death Differ, 29: 246-61. https://doi.org/10.1038/s41418-021-00854-4.
  3. Fiskesund, R., D. Chen, J. Xie, W. Dong, X. Liang, J. Lv, X. Jin, J. Liu, S. Mo, T. Zhang, F. Cheng, Y. Zhou, H. Zhang, K. Tang, J. Ma, Y. Liu, and B. Huang. 2018. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat Commun, 9: 873. https://doi.org/10.1038/s41467-018-03225-9.
  4. Liu, Y., X. Liang, W. Dong, Y. Fang, J. Lv, T. Zhang, R. Fiskesund, J. Xie, J. Liu, X. Yin, X. Jin, D. Chen, K. Tang, J. Ma, H. Zhang, J. Yu, J. Yan, H. Liang, S. Mo, F. Cheng, Y. Zhou, H. Zhang, J. Wang, J. Li, Y. Chen, B. Cui, Z. W. Hu, X. Cao, F. Xiao-Feng Qin, and B. Huang. 2018. Tumor-Repopulating Cells Induce PD-1 Expression in CD8(+) T Cells by Transferring Kynurenine and AhR Activation. Cancer Cell, 33: 480-94.e7. https://doi.org/10.1016/j.ccell.2018.02.005.

Eva Hellström Lindberg

  1. Tobiasson M, Pandzic T, Illman J, Nilsson L, Weström S, Ejerblad E, Olesen G, Björklund A, Olsnes Kittang A, Werlenius O, Lorentz F, Rasmussen B, Cammenga J, Weber D, Lindholm C, Wiggh J, Moen AE, Yip Lundström L, von Bahr L, Baltzer-Sollander K, Dimitriou M, Kytölä S, Walldin G, Ljungman P, Groenbaek K, Mielke S, Jacobsen SEW, Ebeling F, Cavelier L, Smidstrup Friis L, Dybedal I, Hellström-Lindberg E. Early detection of patient-specific measurable residual disease markers predicts outcome in patients with myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Journal of Clinical Oncology, in press, November 2023. https://doi.org/10.1200/JCO.23.01159  *
  2. Moura PL, Mortera-Blanco T, Hofman IJF, Todisco G, Kretzschmar WW, Björklund AC, Creignou M, Hagemann-Jensen M, Ziegenhain C, Granados DC, Barbosa I, Walldin G, Jansson M, Ashley N, Mead AJ, Lundin V, Dimitriou M, Yoshizato T, Woll PS, Ogawa S, Sandberg R, Jacobsen SEW, and Hellström-Lindberg E. Erythroid differentiation intensifies RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts. Cancer Res. 2023 Nov 3. Online ahead of print. https://doi.org/10.1158/0008-5472.CAN-23-3038. *
  3. Todisco G, Creignou M, Bernard E, Björklund AC, Moura PL, Tesi B, Mortera-Blanco T, Sander B, Jansson M, Walldin G, Barbosa I, Reinsbach SE, Hofman IJ, Nilsson C, Yoshizato T, Dimitriou M, Chang D, Olafsdottir S, Venckute Larsson S, Tobiasson M, Malcovati L, Woll P, Jacobsen SEW, Papaemmanuil E and Hellström-Lindberg E. Integrated genomic and transcriptomic analysis improves disease classification and risk stratification of MDS with ring sideroblasts. Clin Cancer Res. 2023;29(20):4256-4267. https://doi.org/10.1158/1078-0432.CCR-23-0538.*
  4. Cieśla M, Cao Thi Ngoc P, Muthukumar1 S, Todisco G, Madej M, Fritz H, Dimitriou M, Incarnato D, Hellström-Lindberg E, Bellodi C. 5m6A-driven SF3B1 translation control steers splicing to direct 1 genome integrity and leukemogenesis. Mol Cell. 2023;83(7):1165-1179.e11. https://doi.org/10.1016/j.molcel.2023.02.024.
  5. Bernard E , Tuechler H, Greenberg PL, Hasserjian RP, Arango JE, Nannya Y, Devlin SM, Creignou M, Pinel P, Monnier L, Medina-Martinez JS, Germing U, van de Loosdrecht AA, Kotsianidis I, Pinheiro RF, Haase D, Santos FPS, Savona MR , Belickova M, Kosmider O, Follo MY , Thol F, Pellagatti A, Klimek VM, Ganster C , Tobiasson M, Kondo-Takaori A, Ishikawa T, Della Porta MG, Sanz G , Chiba S, Ades L, Fenaux P, Palomo L, Elias HK, Kasahara S, Miyazaki Y, Santini V, Solé F, Platzbecker U, Voso MT, Boultwood J, Heuser M, Valent P, Jädersten M, Ohyashiki K, Finelli C, Shih LY , Jansen JH, Fontenay M, Cervera J, Gattermann N, Ebert BL, Bejar RL, Malcovati L, Cazzola M, Ogawa S, Hellström-Lindberg E, Papaemmanuil E. Molecular International Prognosis Scoring System for Myelodysplastic Syndromes. NEJM Evididence 2022;1(7). https://doi.org/10.1056/EVIDoa2200008 *

Petter Höglund

  1. Schmied, L., Luu. T.T., Søndergaard, J.N., Hald, S.H., Meinke, S., Mohammad, D.K., Singh, S.B., Mayer, C., Perinetti Casoni, G., Chrobok, M., Schlums, H., Rota, G., Truong, H.M., Westerberg, L.S., Guarda, G., Alici, E., Wagner, A.K., Kadri, N., Bryceson, Y.T., Saeed, M.B., Höglund, P. SHP-1 localization to the activating immune synapse promotes NK cell tolerance in MHC class I deficiency, Sci. Signal. 16 (780):eabq0752.  https://doi.org/10.1126/scisignal.abq0752 , Epub 2023 Apr 11, 2023. *
  2. Palmblad, J., Sohlberg, E., Nilsson, C., Lindqvist, H., Deneberg, S., Ratcliffe, P., Meinke, S., Mörtberg, A., Klimkowska, M., Höglund, P. Clinical and Immunological Features in ACKR1/DARC Associated Neutropenia. Blood Adv. 2023 Dec 1:bloodadvances.2023010400. https://doi.org/10.1182/bloodadvances.2023010400 . Online ahead of print. *
  3. Rydén, J., Clements, M., Wikman, A., Hellström-Lindberg, E., Edgren, G., Höglund, P. Red blood cell alloimmunization in myelodysplastic syndromes: Associations with sex, DAT-positivity, and increased transfusion needs. Transfusion. 2023 Nov;63(11):2040-2051. https://doi.org/10.1111/trf.17562 . Epub 2023 Oct 11. *
  4. Karlström C, Gryfelt G, Schmied L, Meinke S, Höglund P. Platelet transfusion improves clot formation and platelet function in severely thrombocytopenic haematology patients. Br. J. Haematol. 196, 224-233, 2022. https://doi.org/10.1111/bjh.17820.*
  5. Rydén, J., Edgren, G., Wikman, A., Hellström-Lindberg, E., Höglund, P., Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes, Leukemia, 33, 522-527, 2019. https://doi.org/10.1038/s41375-018-0256-0 *

Sten Eirik W. Jacobsen

  1. Carrelha J, Meng Y, Kettyle LM, Luis TC, Norfo R, Alcolea V, Grasso F, Gambardella A, Grover A, Högstrand K, Lord AM, Sanjuan-Pla A, Woll PS, Nerlov C#, Jacobsen SE#. Hierarchically related lineage-restricted fates of multipotent hematopoietic stem cells, Nature 2018 Feb 1;554(7690):106-111. https://doi.org/10.1038/nature25455 *
  2. Giustacchini A, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, Sopp P, Norfo R, Rodriguez-Meira A, Ashley N, Jamieson L, Vyas P, Anderson K, Segerstolpe A, Qian H, Olsson-Stromberg U, Mustjoki S, Sandberg R, Jacobsen SE#, Mead AJ#. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nature Medicine 2017 Jun;23(6):692-702 (Cover article). https://doi.org/10.1038/nm.4336 *
  3. Woll P, Kjällquist U, Chowdhury O, Doolittle H, Wedge D, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead A, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay I, Clark S,  Dybedal I,  Josefsen D, Fenaux P, Hokland P,  Holm M, Cazzola M,  Malcovati L, Tauro S,  Bowen S, Boultwood J, Pellagatti A, Pimanda J, Unnikrishnan A, Vyas P, Göhring G, Schlegelberger B, Tobiasson M,  Kvalheim G,  Constantinescu S,  Nerlov C,  Nilsson L, Campbell P,  Sandberg R, Papaemmanuil E,  Hellström-Lindberg E,  Linnarsson S,  Jacobsen SE. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 2014 Jun 16;25(6):794-808. https://doi.org/10.1016/j.ccr.2014.03.036 *
  4. Sanjuan-Pla A, Macaulay I, Jensen C, Woll P, Luis T, Mead A, Moore S, Carella C, Matsuoka S, Bouriez- Jones T, Chowdhury O, Stenson L, Lutteropp M, Green J, Facchini R, Boukarabila H, Grover A, Gambardella A, Thongjuea S, Carrelha J, Tarrant P, Atkinson D, Clark SA, Nerlov C#, Jacobsen SE#. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature 2013 Oct 10;502(7470):232-6. https://doi.org/10.1038/nature12495 * 
  5. Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ, Astrand-Grundström I, Strömbeck B, Horvat A, Ferry H, Dhanda RS, Hast R, Rydén T, Vyas P, Göhring G, Schlegelberger B, Johansson B, Hellström-Lindberg E, List A, Nilsson L, Jacobsen SE. Persistent malignant stem cells in del(5q) myelodysplasia in remission. New England Journal of Medicine 2010 Sep 9;363(11):1025-37. https://doi.org/10.1056/NEJMoa0912228 *

Sören Lehmann

  1. Nilsson C, Linde F, Hulegårdh E, Garelius H, Lazarevic V, Antunovic P, Cammenga J, Deneberg S, Eriksson A, Jädersten M, Björkvall CK, Möllgård L, Wennström L, Ölander E, Höglund M, Juliusson G, Lehmann S. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications. Haematologica. 2023 Apr 1;108(4):1015-1025. https://doi.org/10.3324/haematol.2022.281233 
  2. Österroos A, Maia T, Eriksson A, Jädersten M, Lazarevic V, Wennström L, Antunovic P, Cammenga J, Deneberg S, Lorenz F, Möllgård L, Uggla B, Ölander E, Aguiar E, Trigo F, Höglund M, Juliusson G, Lehmann S. A risk score based on real-world data to predict early death in acute promyelocytic leukemia. Haematologica. 2022 Jul 1;107(7):1528-1537. https://doi.org/10.3324/haematol.2021.280093 
  3. Mujahed H, Miliara S, Neddermeyer A, Bengtzén S, Nilsson C, Deneberg S, Cordeddu L, Ekwall K, Lennartsson A, Lehmann S. AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding. Blood. 2020 Jul 16;136(3):339-352. https://doi.org/10.1182/blood.2019002326 
  4. Wang M, Lindberg J, Klevebring D, Nilsson C, Mer AS, Rantalainen M, Lehmann S#, Grönberg H#. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling. Leukemia. 2017 Oct;31(10):2029-2036. https://doi.org/10.1038/leu.2017.48 
  5. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert K, Mick E, Neale BM, Fromer M, Purcell SM, Svantesson O, Landén M, Höglund M, Lehmann S, Gabriel SB, Moran JL, Lander ES, Sullivan PF, Sklar P, Grönberg H, Hultman CM, McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014 Dec 25;371(26):2477-87. https://doi.org/10.1056/NEJMoa1409405 

Jette Lengefeld

  1. Lengefeld J† and Zatulovskiy E†. Cell Size Regulation: Molecular Mechanisms and Physiological Importance, Front Cell Dev Biol 11, 1219294 (2023). https://doi.org/10.3389/fcell.2023.1219294 
  2. Davies D, van der Handel K, Bharadwaj S, Lengefeld J†. Cellular enlargement - a new hallmark of aging?, Front Cell Dev Biol (2022). https://doi.org/10.3389/fcell.2022.1036602 
  3. Lengefeld J†, Cheng CW, Maretich P, Blair M, Hagen H, McReynolds MR, SullivanE, Mayors K, Roberts C, Steiner J, KangJH, Miettinen TP, Manalis SR, Antebi A, Rabinowitz JD, Morrison S, Lees J, Boyer L, Yilmaz O, Amon  A. Cell size is a determinant of stem cell potential during aging, Science Advances, 7 eabk0271, (2021). https://doi.org/10.1126/sciadv.abk0271 
  4. Neurohr G, Terry R, Lengefeld J, Bonney M, Brittingham G, Moretto F, Miettinen T, Pontano Vaites L, Soares L, Paulo J, Harper W, Buratowski S, Manalis S, van Werven F, Holt L, Novak B, Tyson J, Amon A†. Excessive cell growth causes cytoplasm dilution and contributes to senescence, Cell (2019), 176(5):1083-1097.e18. https://doi.org/10.1016/j.cell.2019.01.018 
  5. Lengefeld J, Hotz M, Rollins M, Baetz K, Barral Y†. Budding yeast Wee1 distinguishes spindle pole bodies to guide their pattern of age-dependent segregation, Nature Cell Biology (2017), 19, 941-951. https://doi.org/10.1038/ncb3576   

Sidinh Luc

  1. Somuncular E#, Su T-Y#, Dumral Ö, Johansson A-S, Luc S. Combination of CD49b and CD229 reveals a subset of multipotent progenitors with short-term activity within the hematopoietic stem cell compartment. Stem Cells Translational Medicine. 2023 Nov 3;12(11):720-726. https://doi.org/10.1093/stcltm/szad057 
  2. Gustafsson C, Hauenstein J, Frengen N, Krstic A, Luc S, Månsson R. T-RHEX-RNAseq – a tagmentation-based, rRNA blocked, random hexamer primed RNAseq method for generating stranded RNAseq libraries directly from very low numbers of lysed cells. BMC Genomics. 2023 Apr 17;24(1):205.  https://doi.org/10.1186/s12864-023-09279-4 
  3. Somuncular E, Hauenstein J#, Khalkar P#, Johansson A-S, Dumral Ö, Frengen N, Gustafsson C, Mocci G, Su T-Y, Brouwer H, Trautmann C, Vanlandewijck M, Orkin S, Månsson R, Luc S. CD49b identifies functionally and epigenetically distinct subsets of lineage-biased hematopoietic stem cells. Stem Cell Reports. 2022 Jul 12;17(7):1546-1560. https://doi.org/10.1016/j.stemcr.2022.05.014 Epub 2022 Jun 16.
  4. Peña-Pérez L#, Kharazi S#, Frengen N, Krstic A, Bouderlique T, Hauenstein J, He M, Somuncular E, Wang X, Dahlberg C, Gustafsson C, Johansson A-S, Walfridsson J, Kadri N, Woll P, Kierczak M, Qian H, Westerberg L, Luc S, Månsson R. FOXO dictates initiation of B cell development and myeloid restriction in common lymphoid progenitors. Frontiers in Immunology. 2022 May 4;13:880668. https://doi.org/10.3389/fimmu.2022.880668 eCollection 2022. 

Johan Lund/Evren Alici

  1. Nahi H, Afram G, Uttervall K, Lockmer S, Tätting L, Gahrton G, Kashif M, Alici E, Stromberg O, Klimkowska M, Lund J Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma. Cancer Med. 2023 Nov;12(22):20736-20744. https://doi.org/10.1002/cam4.6640 *
  2. Susek KH, Schwietzer YA, Karvouni M, Gilljam M, Keszei M, Hussain A, Lund J, Kashif M, Lundqvist A, Ljunggren HG, Nahi H, Wagner AK, Alici E. Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy. Cancer Immunol Immunother. 2023 May;72(5):1153-1167. https://doi.org/10.1007/s00262-022-03317-y *
  3. Wålinder G, Genell A, Juliusson G, Svensson R, Santamaria AI, Crafoord J, Carlson K, Knut-Bojanowska D, Veskovski L, Lauri B, Lund J, Turesson I, Hansson M, Blimark CH, Nahi H. Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study. Cancer Rep (Hoboken). 2022 Nov;5(11):e1614. https://doi.org/10.1002/cnr2.1614   
  4. Nahi H, Chrobok M, Meinke S, Gran C, Marquardt N, Afram G, Sutlu T, Gilljam M, Stellan B, Wagner AK, Blomberg P, Holmqvist PH, Walther-Jallow L, Mellström K, Liwing J, Gustafsson C, Månsson R, Klimkowska M, Gahrton G, Lund J, Ljungman P, Ljunggren HG, Alici E. Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. Cell Rep Med. 2022 Jan 28;3(2):100508. https://doi.org/10.1016/j.xcrm.2022.100508 *
  5. Nahi H, Kashif M, Klimkowska M, Karvouni M, Wallblom A, Gran C, Hauenstein J, Frengen N, Gustafsson C, Afram G, Uttervall K, Lund J, Månsson R, Wagner AK, Alici E. Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). Am J Hematol. 2021 Aug 1;96(8):925-933. https://doi.org/10.1002/ajh.26207 *

Vanessa Lundin

  1. Moura P, Mortera Blanco T, Hofman I, Todisco G, Kretzschmar W, Björklund AC, Creignou M, Hagemann-Jensen M, Ziegenhain C, Cabrerizo Granados D, Barbosa B, Walldin G, Jansson M, Ashley N, Mead A, Lundin V, Dimitriou M, Yoshizato T, Woll P, Ogawa S, Sandberg R, Jacobsen SE, Hellström-Lindberg E. Erythroid differentiation intensifies RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts. Cancer Research 2024. https://doi.org/10.1158/0008-5472.CAN-23-3038. *
  2. Cabrerizo Granados D, Barbosa I, Baliakas P, Hellström-Lindberg E, Lundin V. The clinical phenotype of germline RUNX1 mutations in relation to the accompanying somatic variants and RUNX1 isoform expression. Genes, Chromosomes and Cancer 2023;1–6. https://doi.org/10.1002/gcc.23184 * 
  3. Enlund S, Sinha I, Ramilo Amor A, Shirazi Fard S, Pokrovskaja Tamm E, Jiang Q, Lundin V, Nilsson A, Holm F. Malignant DFFB isoform switching promotes leukemia survival in relapse pediatric T-cell acute lymphoblastic leukemia. eJHaem 2022: 1-10. https://doi.org/10.1002/jha2.634 
  4. Lundin V#, Sugden WW#, Theodore LN#, Sousa PM, Han A, Chou S, Wrighton PJ, Cox AG, Ingber DE, Goessling W, Daley GQ, North TE. YAP Regulates Hematopoietic Stem Cell Formation in Response to the Biomechanical Forces of Blood Flow. Developmental Cell 2020: 52(4) 446-460.e5. #Equal contribution. https://doi.org/10.1016/j.devcel.2020.01.006 
  5. Rowe GR, Marion W, Ruiz-Torres S, Boettcher S, Lummertz da Rocha E, Lundin V, Morris V, Chou S, Zhao AM, Kubaczka C, Aumais O, Zhang Y, Shimamura A, Schlaeger TM, North TE, Ebert BL, Wells S, Daley GQ. An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor differentiation. Blood Advances 2020: 4(19): 4679-4692.
    https://doi.org/10.1182/bloodadvances.2020001593 

Isabelle Magalhaes

  1. Schoutrop E, Poiret T, El Serafi I, Zhao Y, He R, Moter A, Henriksson J, Hassan M, Magalhaes I#, Mattsson J#. Tuned activation of MSLN-CAR T cells induces superior anti-tumor responses in ovarian cancer models. Journal for ImmunoTherapy of Cancer. 2023. https://doi.org/10.1136/jitc-2022-005691 
  2. Schoutrop E, Renken S, Micallef NilssonI, Hahn P, Poiret P, Kiessling R, Wickström SL, Mattsson J, Magalhaes I. Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality. Oncoimmunology. 2022.  https://doi.org/10.1080/2162402X.2022.2093426
  3. Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L, Carlson JW, Lehti K, Hassan M#, Magalhaes I#, Mattsson J#. Mesothelin-specific CAR T cells target ovarian cancer. Cancer Res. 2021. https://doi.org/10.1158/0008-5472.CAN-20-2701
  4. Magalhaes I*, Fernebro J*, Abd Own S, Glaessgen D, Corvigno S, Remberger M, Mattsson J, Dahlstrand H. Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor. Adv Ther. 2020 Dec;37(12):5023-5031. https://doi.org/10.1007/s12325-020-01520-w
  5. Magalhaes I, Kalland I, Kochenderfer JN, Österborg A, Uhlin M, Mattsson J. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile. J Immunother. 2018. https://doi.org/10.1097/CJI.0000000000000193 *

Nicole Marquardt

  1. Brownlie D, von Kries A, Valenzano G, Wild N, Yilmaz E, Säfholm J, Al-Ameri M, Alici E, Ljunggren H-G, Schliemann I, Aricak O, Haglund de Flon F, Michaëlsson J, Marquardt N. Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8+ T cells towards the center of human lung tumors. OncoImmunology. 2023 Jul 11;12(1):2233402. https://doi.org/10.1080/2162402X.2023.2233402
  2. Brownlie D, Rødahl I, Varnaitė R, Asgeirsson H, Glans H, Falck-Jones S, Vangeti S, Buggert M, Ljunggren H-G, Michaëlsson J, Gredmark-Russ S, Smed-Sörensen A, Marquardt N. Comparison of Lung-Homing Receptor Expression and Activation Profiles on NK Cell and T Cell Subsets in COVID-19 and Influenza. Front Immunol. 2022;13:834862. https://doi.org/10.3389/fimmu.2022.834862 
  3. Brownlie D, Scharenberg M, Mold JE, Hård J, Kekäläinen E, Buggert M, Nguyen S, Wilson JN, Al-Ameri M, Ljunggren H-G, Marquardt N, Michaëlsson J. Expansions of adaptive-like NK cells with a tissue-resident phenotype in human lung and blood. PNAS; 2021;118(11):e2016580118. https://doi.org/10.1073/pnas.2016580118
  4. Evren E, Ringqvist E, Tripathi KP, Sleiers N, Rives IC, Alisjahbana A, Gao Y, Sarhan D, Halle T, Sorini C, Lepzien R, Marquardt N, Michaëlsson J, Smed-Sörensen A, Botling J, Karlsson MCI, Villablanca EJ, Willinger T. Distinct developmental pathways from blood monocytes generate human lung macrophage diversity. Immunity. 2020 Dec 23. https://doi.org/10.1016/j.immuni.2020.12.003
  5. Marquardt N, Kekäläinen E, Chen P, Lourda M, Wilson JN, Scharenberg M, Bergman P, Al-Ameri M, Hård J, Mold JE, Ljunggren H-G, Michaëlsson J. Unique transcriptional and protein-expression signature in human lung tissue-resident NK cells. Nature Commun. Nature Publishing Group; 2019 Aug 26;10(1):3841–12. https://doi.org/10.1038/s41467-019-11632-9 

William Nyberg

  1. Nyberg WA, Ark J, To A, Clouden S, Reeder G, Muldoon JJ, Chung JY, Xie WX, Allain V, Steinhart Z, Chang C, Talbot A, Kim S, Rosales A, Havlik LP, Pimentel H, Asokan A, Eyquem J. An evolved AAV variant enables efficient genetic engineering of murine T cells. Cell, 186(2), 446-460.e19 (2023). https://doi.org/10.1016/j.cell.2022.12.022
  2. Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature, 609(7925), 174-182 (2022). https://doi.org/10.1038/s41586-022-05126-w
  3. Blaeschke F, Chen YY, Apathy R, Daniel B, Chen AY, Chen PA, Sandor K, Zhang W, Li Z, Mowery CT, Yamamoto TN, Nyberg WA, To A, Yu R, Bueno R, Kim MC, Schmidt R, Goodman DB, Feuchtinger T, Eyquem J, Jimmie Ye C, Carnevale J, Satpathy AT, Shifrut E, Roth TL, Marson A. Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. Cell, 186(19), 4216-4234.e33 (2023). https://doi.org/10.1016/j.cell.2023.08.013
  4. Nyberg WA, Eyquem J. Genome Editing Applications in Cancer T Cell Therapy.
    Genome Editing in Drug Discovery, Chapter 16, 213-259, ISBN: 9781119671404 (2022).
  5. Nyberg WA, Velasquez-Pulgarin DA, He T, Sjöstrand M, Pellé L, Covacu R, Espinosa A.
    The bromodomain protein TRIM28 controls the balance between growth and invasiveness in melanoma. EMBO reports, 24(1), e54944 (2022). https://doi.org/10.15252/embr.202254944 

Hong Qian

  1. Xiao, P., Sandhow, L., Heshmati, Y., Kondo, M., Bouderlique, T., Dolinska, M., Johansson, A.S., Sigvardsson, M., Ekblom, M., Walfridsson, J., and Qian, H. Distinct roles of mesenchymal stem and progenitor cells during the development of acute myeloid leukemia in mice. Blood Advances, 2018, 2, 1480-1494. https://doi.org/10.1182/bloodadvances.2017013870
  2. Xiao, P., Dolinska, M., Sandhow, L., Kondo, M., Johansson, A.S., Bouderlique, T., Zhao, Y., Li, X., Dimitriou, M,. Rassidakis, G.Z., Hellstrom-Lindberg, E., Minato, N., Walfridsson, J., Scadden, D.T., Sigvardsson, M. and Qian, H.. Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm. Blood Advances, 2018, 2:534-548. https://doi.org/10.1182/bloodadvances.2017013599
  3. Cai H#,  Kondo M#,  Sandhow L,  Xiao P, Johansson AS,  Sasaki T,  Zawacka-Pankau J,  Tryggvason K, Ungerstedt J,  Walfridsson J,  Ekblom M,  Qian H.  Critical role of Lama4 for hematopoiesis regeneration and acute myeloid leukemia progression. Blood 2022 139;20 3040-3057.  https://doi.org/10.1182/blood.2021011510
  4. Dolinska M#,  Cai H#,  Månsson A#,  Shen J, Xiao P,  Bouderlique T,  Li X, Leonard E,  Chang M,  Gao Y, Medina JP,  Kondo M,  Sandhow L, Johansson AS,  Deneberg S,  Söderlund S, Jädersten M,  Ungerstedt J,  Tobiasson M, Östman A,  Mustjoki S,  Stenke L, Le Blanc K,  Hellström-Lindberg E,  Lehmann S,  Ekblom M, Olsson-Strömberg U,  Sigvardsson M,  Qian H.  Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option. Blood 2023 142;1 73-89. https://doi.org/10.1182/blood.2022016896 
  5. Sandhow L, Cai H, Leonard E, Xiao P, Tomaipitinca L, Månsson A, Kondo M, Sun X,  Johansson AS, Tryggvason K, Kasper M, Järås M,  Qian H.  Skin mesenchymal niches maintain and protect AML-initiating stem cells. The Journal of Experimental Medicine 2023 220;10   https://doi.org/10.1084/jem.20220953  

Marc Raaijmakers

  1. Raaijmakers MHGP#, Mukherjee S, Guo S, Kobayashi T, Zhang S, Schoonmaker J,  Ebert B, Lin C, Rommens J, Scadden DT#. Osteoprogenitor cell dysfunction induces myelodysplasia and secondary leukemia. Nature 2010 Apr 8;464 (7290):852-7. https://doi.org/10.1038/nature08851 
  2. NA Zambetti, Z Ping, S Chen, K. J. G. Kenswil, M.A. Mylona, M.A. Sanders, R.M. Hoogenboezem, E.M. J. Bindels, M.N. Adisty, P.M.H. Van Strien, C.S. van der Leije, T.M. Westers, E.M.P. Cremers, C. Milanese, P.G. Mastroberardino, J.P.T.M. van Leeuwen, B.C.J. van der Eerden, I.P. Touw, T.W. Kuijpers, R.Kanaar, A.A. van de Loosdrecht, T.Vogl and Raaijmakers MHGP. Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia. Cell Stem Cell. 2016 Nov 3;19(5):613-627. https://doi.org/10.1016/j.stem.2016.08.021 
  3. KJG Kenswil, P Pisterzi, G Sánchez-Duffhues, C van Dijk, A Lolli, C Knuth, B Vanchin, AC Jaramillo, RM Hoogenboezem, MA Sanders, J Feyen, T Cupedo, IG Costa, R Li, EMJ Binders, K Lodder, B Blom, PK Bos, M-J Goumans, P ten Dijke, Raaijmakers MHGP. Endothelium-derived stromal cells contribute to hematopoietic bone marrow niche formation. Cell Stem Cell. 2021 Apr 28, 4, p. 653-670.e11. https://doi.org/10.1016/j.stem.2021.01.006 
  4. Feyen J, Ping Z, Chen L, Van Dijk C, Van Tienhoven TVD, Van Strien PMH, Hoogenboezem RM, Wevers MJW, Sanders MA, Touw IP, Raaijmakers MHGP. Myeloid cells promote interferon signaling-associated deterioration of the hematopoietic system. Nature Commun. 2022 Dec 10;13(1):7657. https://doi.org/10.1038/s41467-022-35318-x 
  5. Chen L, Pronk E, van Dijk C, Bian Y, Feyen J, van Tienhoven T, Yildirim M, Pisterzi P, de Jong MME, Bastidas A, Hoogenboezem RM, Wevers C, Bindels EM, Löwenberg B, Cupedo T, Sanders MA, Raaijmakers MHGP. A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML. Blood Cancer Discov. 2023 Sep 1;4(5):394-417. https://doi.org/10.1158/2643-3230.BCD-23-0043 

Magnus Tobiasson

  1. Klimkowska M and Nannya Y, Gran C, Douaghi Y, Ogawa S, Nahi H, Tobiasson M. Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder. Blood. 2021;137(9):1260-3. https://doi.org/10.1182/blood.2020007555 
  2. Lindholm C, Olofsson E, Jädersten M, Ljungman P, Ejerblad E, Tobiasson M. Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study. Bone Marrow Transplant. 2022;57(4):598-60. https://doi.org/10.1038/s41409-022-01582-0
  3. Jädersten M, Boriskina K, Lindholm C, Weström S, Cavelier L, Hellström-Lindberg E, Mielke S, Tobiasson M. Limited benefit in patients with MDS receiving venetoclax and azacytidine as a bridge to allogeneic stem cell transplantation. Leuk Lymphoma. 2022;63(3):755-8. https://doi.org/10.1080/10428194.2021.2002319 *
  4. Nannya Y#, Tobiasson M#, Sato S, Bernard E, Ohtake S, Takeda J, Creignou M, Zhao L, Kusakabe M, Shibata Y, Nakamura N, Watanabe M, Hiramoto N, Shiozawa Y, Shiraishi Y, Tanaka H, Yoshida K, Kakiuchi N, Makishima H, Nakagawa MM, Usuki K, Watanabe M, Imada K, Handa H, Taguchi M, Kiguchi T, Ohyashiki K, Ishikawa T, Takaori-Kondo A, Tsurumi H, Kasahara S, Chiba S, Naoe T, Miyano S, Papaemmanuil E, Miyazaki Y, Hellstrom Lindberg E, Ogawa S. Post-azacitidine clone size predicts outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. Blood Adv. 2023 Jul 25;7(14):3624-3636. https://doi.org/10.1182/bloodadvances.2022009564 

Michael Uhlin

  1. Sandoz PA, Kuhnigk K, Szabo EK, Thunberg S, Erikson E, Sandström N, Verron Q, Brech A, Watzl C, Wagner AK, Alici E, Malmberg KJ, Uhlin M, Önfelt B: Modulation of lytic molecules restrain serial killing in γδ T lymphocytes. Nature Communications (2023). Sep 27;14(1):6035. https://doi.org/10.1038/s41467-023-41634-7 *
  2. Arruda LCM, Stikvoort A, Lambert M, Jin L, Rivera LS, Alves RMP, De Moura TR, Mim C, Lehmann S, Axelsson-Robertson R, Dick JE, Mattsson J, Önfelt B, Carlsten M, Uhlin M: A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo. Haematologica (2022) https://doi.org/10.3324/haematol.2021.279486 *
  3. Foord E, Arruda L, Gaballa A, Klynning C, Uhlin M: Characterization of ascites- and tumor-infiltrating γδ T-cells reveals distinct repertoires and a beneficial role in ovarian cancer. Science Translational Medicine (2021) 13(577):eabb0192. https://doi.org/10.1126/scitranslmed.abb0192 
  4. Arruda LCM, Gaballa A, Uhlin M: Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis. Blood Adv (2019) 3(21):3436-3448. https://doi.org/10.1182/bloodadvances.2019000682 
  5. Rådestad E, Sundin M, Törlén J, Thunberg S, Önfelt B, Ljungman P, Watz E, Mattsson J, Uhlin M: Individualization of Hematopoietic Stem Cell Transplantation Using Alpha/Beta T-Cell Depletion. Front Immunol (2019). https://doi.org/10.3389/fimmu.2019.00189 

Johanna Ungerstedt

  1. Söderlund S, Boey D, van Midden W, Kjellander M, Axe K, Qian H, Dahlin JS, Ungerstedt J. A proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis.  J Allergy Clin Immunol 2023 Jul; 152(1):205-213. https://doi.org/10.1016/j.jaci.2023.01.033 *
  2. Ungerstedt J, Ljung C, Klimkowska M, Gülen T. Clinical Outcomes of Adults with Systemic Mastocytosis: A 15-Year Multidisciplinary Experience. Cancers (Basel). 2022 Aug 16;14(16):3942-53. https://doi.org/10.3390/cancers14163942 
  3. Moreno Berggren D, Kjellander M,, Backlund E, Engvall M, Garelius H, Lorenz F, Nilsson L, Rasmussen B, Lehmann S, Hellström-Lindberg E, Jädersten M, Ungerstedt J, Ejerblad E. Prognostic scoring systems and comorbidities in Chronic Myelomonocytic Leukemia: a nationwide population-based study. Br J Haematol. 2021 Feb;192(3):474-483. https://doi.org/10.1111/bjh.16790 *
  4. Salomonsson M, Ungerstedt J, Alvarado-Vazquez PA, Hallgren J. Demonstration of human mast cell progenitors in the bone marrow. Allergy. 2020 Feb;75(2):456-460. https://doi.org/10.1111/all.14004

Arnika Kathleen Wagner

  1. Nahi H, Chrobok M, Meinke S, Gran C, Marquardt N, Afram G, Sutlu T, Gilljam M, Stellan B, Wagner AK, Blomberg P, Holmqvist PH, Walther-Jallow L, Mellstrom K, Liwing J, Gustafsson C, Mansson R, Klimkowska M, Gahrton G, Lund J, Ljungman P, Ljunggren HG, Alici E. 2022. Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. Cell Rep Med 3:100508. https://doi.org/10.1016/j.xcrm.2022.100508 *
  2. Schwietzer YA SK, Chen Z, Alici E, Wagner AK. A tractable microscopy- and flow cytometry-based method to measure Natural Killer cell-mediated killing and infiltration of tumor spheroids. 2023. Methods in Cell Biol 178:43-61. https://doi.org/10.1016/bs.mcb.2022.07.011 *
  3. Susek KH, Schwietzer YA, Karvouni M, Gilljam M, Keszei M, Hussain A, Lund J, Kashif M, Lundqvist A, Ljunggren HG, Nahi H, Wagner AK, Alici E. 2022. Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy. Cancer Immunol Immunother 72(5):1153-1167. https://doi.org/10.1007/s00262-022-03317-y *
  4. Wagner AK, Kadri N, Tibbitt C, van de Ven K, Bagawath-Singh S, Oliinyk D, LeGresley E, Campbell N, Trittel S, Riese P, Ribacke U, Sandalova T, Achour A, Karre K, Chambers BJ. 2022. PD-1 expression on mouse intratumoral NK cells and its effects on NK cell phenotype. iScience 25:105137. https://doi.org/10.1016/j.isci.2022.105137
  5. Nahi H, Kashif M, Klimkowska M, Karvouni M, Wallblom A, Gran C, Hauenstein J, Frengen N, Gustafsson C, Afram G, Uttervall K, Lund J, Mansson R, Wagner AK#, Alici E#. 2021. Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). Am J Hematol 96:925-933. https://doi.org/10.1002/ajh.26207 *

Petter Woll

  1. Giannakopoulou E,  Lehander M, Virding Culleton S,  Yang W,  Li Y, Karpanen T,  Yoshizato T,  Rustad EH, Nielsen MM,  Bollineni RC,  Tran TT, Delic-Sarac M,  Gjerdingen TJ,  Douvlataniotis K,  Laos M, Ali M,  Hillen A,  Mazzi S, Chin DWL,  Mehta A,  Holm JS, Bentzen AK,  Bill M,  Griffioen M, Gedde-Dahl T,  Lehmann S,  Jacobsen SEW,  Woll PS,  Olweus J. A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo. Nature Cancer (IF 22.7), 2023, 4:1474-1490. https://doi.org/10.1038/s43018-023-00642-8 *
  2. Belander Strålin K,  Carrelha J, Winroth A,  Ziegenhain C,  Hagemann-Jensen M,  Kettyle LM, Hillen A,  Högstrand K,  Markljung E, Grasso F,  Seki M,  Mazzi S, Meng Y,  Wu B,  Chari E, Lehander M,  Sandberg R,  Woll PS, Jacobsen SEW. Platelet and myeloid lineage biases of transplanted single perinatal mouse hematopoietic stem cells. Cell Research (IF 44.1), 2023, 33:883-886. https://doi.org/10.1038/s41422-023-00866-4 *
  3. Matsuoka S#, Facchini R#,  Luis TC#,  Carrelha J#, Woll PS#,  Mizukami T,  Wu B, Boukarabila H,  Buono M,  Norfo R, Arai F,  Suda T,  Mead A, Nerlov C,  Jacobsen SEW. Loss of endothelial membrane KIT Ligand affects systemic KIT ligand levels but not bone marrow hematopoietic stem cells. Blood (IF 22.1), 2023, 142:1622-1632. https://doi.org/10.1182/blood.2022019018 *
  4. Chin DWL, Yoshizato T, Culleton SV, Grasso F, Barbachowska M, Ogawa S, Jacobsen SEJW#, Woll PS#. Aged healthy mice acquire clonal hematopoiesis mutations. Blood (IF 22.1), 2022, 139:629-634. https://doi.org/10.1182/blood.2021014235 *
  5. Ali M, Giannakopoulou E, Li Y, Lehander M, Virding Culleton S, Yang W, Knetter C, Odabasi MC, Bollineni RC, Yang X, Foldvari Z, Böschen ML, Taraldsrud E, Strønen E, Toebes M, Hillen A, Mazzi S, de Ru AH, Janssen GMC, Kolstad A, Tjønnfjord GE, Lie BA, Griffioen M, Lehmann S, Osnes LT, Buechner J, Garcia KC, Schumacher TN, van Veelen PA, Leisegang M, Jacobsen SEW, Woll P, Olweus J. T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. Nature Biotechnology (IF 68.1), 2022, 40:488-498. https://doi.org/10.1038/s41587-021-01089-x *
Content reviewer:
Eva Hellström Lindberg
03-09-2024